Published in J Cell Mol Med on November 05, 2007
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics (2011) 1.50
ADAM8 as a drug target in pancreatic cancer. Nat Commun (2015) 1.46
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med (2013) 0.92
ADAM8: a new therapeutic target for asthma. Expert Opin Ther Targets (2009) 0.86
Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. Int J Biol Sci (2016) 0.85
ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer (2012) 0.82
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets (2015) 0.81
Structure of human ADAM-8 catalytic domain complexed with batimastat. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.80
Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. Br J Cancer (2012) 0.79
N-glycosylation regulates ADAM8 processing and activation. J Biol Chem (2014) 0.78
Deficiency of the metalloproteinase-disintegrin ADAM8 is associated with thymic hyper-cellularity. PLoS One (2010) 0.78
ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. Int J Mol Sci (2016) 0.78
Enzymatic aspects in ENT cancer-Matrix metalloproteinases. J Med Life (2014) 0.77
Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer (2014) 0.76
Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis. Cancer Microenviron (2016) 0.75
A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models. Sci Rep (2016) 0.75
Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. Sci Rep (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Pancreatic cancer. Lancet (2004) 11.63
Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res (2001) 2.14
ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol (1995) 2.00
Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int Immunol (1990) 1.71
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 1.67
Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer (2005) 1.63
Pancreatic cancer: from bench to 5-year survival. Pancreas (2006) 1.49
Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol (2006) 1.32
Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem (2003) 1.27
ADAM8: a novel osteoclast stimulating factor. J Bone Miner Res (2001) 1.24
The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem (2002) 1.23
Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res (2006) 1.23
Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol (2004) 1.19
ADAM family proteins in the immune system. Immunol Today (1999) 1.17
Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem (2004) 1.16
ADAMs, cell migration and cancer. Cancer Metastasis Rev (2006) 1.13
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett (2002) 1.13
ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer (2004) 1.11
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res (2006) 1.10
ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res (2004) 1.10
Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration. J Neurosci (2000) 1.06
Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun (2001) 1.02
CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics (1997) 0.99
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch (2006) 0.96
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol (2004) 0.92
Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem (2006) 0.92
Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res (2007) 0.90
Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels. Brain Res (2006) 0.79
Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature (2000) 6.34
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
Cloud-radiative forcing and climate: results from the Earth radiation budget experiment. Science (1989) 3.58
Immunolocalization of sarcolemmal dihydropyridine receptor and sarcoplasmic reticular triadin and ryanodine receptor in rabbit ventricle and atrium. J Cell Biol (1995) 3.28
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol (2000) 2.93
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas (2004) 2.85
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A (1999) 2.82
Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg (2000) 2.73
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Pancreatic fistula after pancreatic head resection. Br J Surg (2000) 2.44
Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg (1992) 2.38
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res (2001) 2.24
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
PDGF-D, a new protease-activated growth factor. Nat Cell Biol (2001) 2.17
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
[Phenprocoumon-induced necrotizing hepatitis]. Dtsch Med Wochenschr (2001) 2.08
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy (1982) 2.06
Neuroimmune appendicitis. Lancet (1999) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. Z Gastroenterol (1992) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer (1994) 1.97
Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg (2007) 1.92
Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg (2001) 1.87
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg (2011) 1.82
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem (2001) 1.76
ESPEN guidelines on nutrition in acute pancreatitis. European Society of Parenteral and Enteral Nutrition. Clin Nutr (2002) 1.75
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer (1995) 1.67
The role of infection in acute pancreatitis. Gut (1999) 1.66
On the requirements of ascorbic acid in man: steady-state turnover and body pool in smokers. Am J Clin Nutr (1981) 1.66
Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet (2006) 1.63
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci (2003) 1.60
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res (2001) 1.55
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun (1998) 1.52
Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg (1995) 1.52
Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer. Eur J Cancer Clin Oncol (1988) 1.52
A pancreatic cancer-specific expression profile. Oncogene (1996) 1.50
Vitamin A teratogenicity and risk assessment in the macaque retinoid model. Reprod Toxicol (2000) 1.50
Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg (2008) 1.50
Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. Gastroenterology (1997) 1.49
[S3-guidelines--sedation in gastrointestinal endoscopy]. Z Gastroenterol (2008) 1.47
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ (2007) 1.46
Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci U S A (1996) 1.44
Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg (2005) 1.42
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 1.41
Randomized controlled trial of ultrasonic dissection versus standard surgical technique in open left hemicolectomy or total gastrectomy. Br J Surg (2011) 1.41
Normal lysosomal morphology and function in LAMP-1-deficient mice. J Biol Chem (1999) 1.41
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol (2006) 1.41
Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg (1996) 1.40
[In-hospital mortality of acute hemorrhage of esophageal/fundus varices: an analysis of blood glucose level and other risk factors in 99 consecutive patients]. Dtsch Med Wochenschr (2007) 1.39
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
NOTES for the cardia: antireflux therapy via transluminal access. Endoscopy (2010) 1.38
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 1.37
Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen (2001) 1.37
The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett (2001) 1.37
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology (1999) 1.36
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Tumor microenvironment and progression of pancreatic cancer. Exp Oncol (2010) 1.32
Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res (1994) 1.32
Herpes simplex virus sepsis and acute liver failure. Clin Transplant (2009) 1.32
Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology (1992) 1.31
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med (1999) 1.31
Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development (1996) 1.30
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Effect of micro- and macroporosity of bone substitutes on their mechanical properties and cellular response. J Mater Sci Mater Med (2003) 1.30
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg (1999) 1.27
Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer (1995) 1.26
Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology (1997) 1.26
Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience (2002) 1.26